Delvys Rodríguez‐Abreu

47.2k total citations · 11 hit papers
186 papers, 18.0k citations indexed

About

Delvys Rodríguez‐Abreu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Delvys Rodríguez‐Abreu has authored 186 papers receiving a total of 18.0k indexed citations (citations by other indexed papers that have themselves been cited), including 152 papers in Oncology, 117 papers in Pulmonary and Respiratory Medicine and 32 papers in Cancer Research. Recurrent topics in Delvys Rodríguez‐Abreu's work include Cancer Immunotherapy and Biomarkers (102 papers), Lung Cancer Treatments and Mutations (93 papers) and Lung Cancer Diagnosis and Treatment (38 papers). Delvys Rodríguez‐Abreu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (102 papers), Lung Cancer Treatments and Mutations (93 papers) and Lung Cancer Diagnosis and Treatment (38 papers). Delvys Rodríguez‐Abreu collaborates with scholars based in Spain, United States and Japan. Delvys Rodríguez‐Abreu's co-authors include Maya Gottfried, Tibor Csőszi, Rina Hui, Martin Reck, Nir Peled, Ali Tafreshi, Katsuyuki Hotta, Sinéad Cuffe, Suman Rao and Julie R. Brahmer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Delvys Rodríguez‐Abreu

175 papers receiving 17.8k citations

Hit Papers

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–... 2016 2026 2019 2022 2016 2018 2019 2019 2021 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
    2016 7.1k citations Martin Reck, Delvys Rodríguez‐Abreu et al. profile →
  2. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
    2018 2.6k citations Mark A. Socinski, Robert M. Jotte et al. profile →
  3. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
    2019 1.1k citations Martin Reck, Delvys Rodríguez‐Abreu et al. Journal of Clinical Oncology profile →
  4. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
    2019 688 citations Martin Reck, Tony Mok et al. profile →
  5. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
    2021 616 citations Martin Reck, Delvys Rodríguez‐Abreu et al. Journal of Clinical Oncology profile →
  6. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
    2020 491 citations Alejandro Navarro, Tibor Csőszi et al. Journal of Clinical Oncology profile →
  7. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
    2023 460 citations Heather A. Wakelee, Moïshe Liberman et al. profile →
  8. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
    2020 405 citations Robert M. Jotte, Federico Cappuzzo et al. profile →
  9. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
    2021 316 citations Mark A. Socinski, Makoto Nishio et al. profile →
  10. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
    2022 296 citations Byoung Chul Cho, Delvys Rodríguez‐Abreu et al. profile →
  11. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
    2021 165 citations Michael Boyer, Mehmet Alı Nahıt Şendur et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Delvys Rodríguez‐Abreu Spain 38 15.1k 10.1k 3.5k 2.0k 2.0k 186 18.0k
Katsuyuki Hotta Japan 40 11.2k 0.7× 8.7k 0.9× 2.0k 0.6× 1.7k 0.9× 2.1k 1.0× 288 14.1k
Maya Gottfried Israel 33 10.7k 0.7× 7.7k 0.8× 2.0k 0.6× 1.7k 0.9× 1.9k 1.0× 156 13.3k
Gregory M. Lubiniecki United States 25 12.2k 0.8× 8.1k 0.8× 2.9k 0.8× 1.8k 0.9× 1.4k 0.7× 56 14.3k
Scott Gettinger United States 58 10.3k 0.7× 6.8k 0.7× 2.8k 0.8× 1.7k 0.9× 2.8k 1.4× 258 13.2k
Rina Hui Australia 46 11.4k 0.8× 7.3k 0.7× 2.5k 0.7× 1.9k 0.9× 1.9k 0.9× 173 14.2k
Johan Vansteenkiste Belgium 41 12.9k 0.9× 13.2k 1.3× 1.7k 0.5× 2.9k 1.4× 4.4k 2.2× 169 18.6k
Igor Bondarenko United States 54 13.3k 0.9× 9.0k 0.9× 1.9k 0.5× 3.6k 1.8× 3.3k 1.6× 317 17.7k
Laura Q.M. Chow United States 44 9.1k 0.6× 4.6k 0.5× 3.0k 0.9× 1.6k 0.8× 2.9k 1.4× 159 12.4k
Craig Devoe United States 17 10.3k 0.7× 3.9k 0.4× 4.5k 1.3× 1.3k 0.6× 2.3k 1.1× 47 12.7k
Benjamin Besse France 64 12.2k 0.8× 10.4k 1.0× 2.2k 0.6× 3.8k 1.9× 5.6k 2.8× 708 18.8k

Countries citing papers authored by Delvys Rodríguez‐Abreu

Since Specialization
Citations

This map shows the geographic impact of Delvys Rodríguez‐Abreu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Delvys Rodríguez‐Abreu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Delvys Rodríguez‐Abreu more than expected).

Fields of papers citing papers by Delvys Rodríguez‐Abreu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Delvys Rodríguez‐Abreu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Delvys Rodríguez‐Abreu. The network helps show where Delvys Rodríguez‐Abreu may publish in the future.

Co-authorship network of co-authors of Delvys Rodríguez‐Abreu

This figure shows the co-authorship network connecting the top 25 collaborators of Delvys Rodríguez‐Abreu. A scholar is included among the top collaborators of Delvys Rodríguez‐Abreu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Delvys Rodríguez‐Abreu. Delvys Rodríguez‐Abreu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Clavo, Bernardino, Mario Federico, Gregorio Martı́nez-Sánchez, et al.. (2025). Ozone Treatment in the Management of Chemotherapy-Induced Peripheral Neuropathy: A Review of Rationale and Research Directions. Cancers. 17(14). 2278–2278.
2.
Timilsina, Mohan, María Torrente, Mariano Provencio, et al.. (2025). Large language model vs. traditional machine learning: Evaluating predictive models for early detection of tumor relapse. Expert Systems with Applications. 283. 127641–127641. 1 indexed citations
3.
Wakelee, Heather A., Shugeng Gao, Moïshe Liberman, et al.. (2025). LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671. Annals of Oncology. 36. S1607–S1608.
4.
5.
Garassino, Marina Chiara, Heather A. Wakelee, Jonathan Spicer, et al.. (2024). Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8012–8012. 2 indexed citations
6.
7.
Rodríguez‐Abreu, Delvys, Byoung Chul Cho, Tibor Csőszi, et al.. (2024). Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC). Cancer Research. 84(7_Supplement). CT253–CT253. 2 indexed citations
8.
Provencio, Mariano, Haroon Hasan, Begoña Campos, et al.. (2024). Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer. Clinical & Translational Oncology. 26(6). 1384–1394. 3 indexed citations
9.
Wakelee, Heather A., Moïshe Liberman, Terufumi Kato, et al.. (2023). KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.. Journal of Clinical Oncology. 41(17_suppl). LBA100–LBA100. 11 indexed citations
10.
Clavo, Bernardino, Yolanda Ramallo‐Fariña, Mario Federico, et al.. (2023). Effects of Ozone Treatment on Health-Related Quality of Life and Toxicity Induced by Radiotherapy and Chemotherapy in Symptomatic Cancer Survivors. International Journal of Environmental Research and Public Health. 20(2). 1479–1479. 7 indexed citations
11.
Levy, Benjamin, Fabrice Barlési, Luis Paz‐Ares, et al.. (2022). Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer. 166. 107–113. 6 indexed citations
12.
Clavo, Bernardino, Gregorio Martı́nez-Sánchez, Francisco Rodrı́guez-Esparragón, et al.. (2021). Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial. International Journal of Molecular Sciences. 22(6). 2802–2802. 23 indexed citations
13.
Boyer, Michael, Mehmet Alı Nahıt Şendur, Delvys Rodríguez‐Abreu, et al.. (2021). Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Journal of Clinical Oncology. 39(21). 2327–2338. 165 indexed citations breakdown →
14.
15.
Reck, Martin, Tony Mok, Mark A. Socinski, et al.. (2020). 1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations. Annals of Oncology. 31. S837–S838. 12 indexed citations
16.
Provencio, Mariano, Enric Carcereny, Delvys Rodríguez‐Abreu, et al.. (2019). Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Translational Lung Cancer Research. 8(4). 461–475. 43 indexed citations
17.
Clavo, Bernardino, Francisco Rodrı́guez-Esparragón, Delvys Rodríguez‐Abreu, et al.. (2019). Modulation of Oxidative Stress by Ozone Therapy in the Prevention and Treatment of Chemotherapy-Induced Toxicity: Review and Prospects. Antioxidants. 8(12). 588–588. 72 indexed citations
18.
Reck, Martin, Mark A. Socinski, Federico Cappuzzo, et al.. (2017). Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150). Annals of Oncology. 28. xi31–xi31. 32 indexed citations
19.
Franco, Fernando, Javier Lavernia, Josep Gumà, et al.. (2016). Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group. Clinical Lymphoma Myeloma & Leukemia. 17(3). 186–191. 27 indexed citations
20.
Rodríguez‐Abreu, Delvys, et al.. (2003). Linfomas no hodgkinianos agresivos: ¿Después del CHOP sólo el CHOP?. SHILAP Revista de lepidopterología. 42(1). 79–88. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katsuyuki Hotta Breakdown of academic impact, for papers by Maya Gottfried Breakdown of academic impact, for papers by Gregory M. Lubiniecki Breakdown of academic impact, for papers by Scott Gettinger Breakdown of academic impact, for papers by Rina Hui Breakdown of academic impact, for papers by Johan Vansteenkiste Breakdown of academic impact, for papers by Igor Bondarenko Breakdown of academic impact, for papers by Laura Q.M. Chow Breakdown of academic impact, for papers by Craig Devoe Breakdown of academic impact, for papers by Benjamin Besse
Rankless by CCL
2026